Sarcomatoid carcinoma of the lung epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 25: Line 25:


===Race===
===Race===
*There is no racial predilection to [disease name].
*There is no racial predilection to sarcomatoid carcinoma of the lung.
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
 
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*[Disease name] affects men and women equally.

Revision as of 17:13, 31 December 2018

Sarcomatoid Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sarcomatoid Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

Echocardiography and Ultrasound

CT-Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sarcomatoid carcinoma of the lung epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sarcomatoid carcinoma of the lung epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sarcomatoid carcinoma of the lung epidemiology and demographics

CDC on Sarcomatoid carcinoma of the lung epidemiology and demographics

Sarcomatoid carcinoma of the lung epidemiology and demographics in the news

Blogs on Sarcomatoid carcinoma of the lung epidemiology and demographics

Directions to Hospitals Treating Sarcomatoid carcinoma of the lung

Risk calculators and risk factors for Sarcomatoid carcinoma of the lung epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

  • The prevalence of sarcomatoid carcinoma of the lung is approximately 0.4 cases per 100,000 individuals worldwide.[1]
  • Sarcomatoid carcinoma comprises of 0.3% to 1.3% of total lung malignancies.[2]
  • The overall prevalence of sarcomatoid carcinoma of the lung is 0.1% to 0.4% of all non-small cell lung malignancies.[3]

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Sarcomatoid carcinoma of the lung is more commonly diagnosed among patients aged 65 to 75 years old.[4]
  • Sarcomatoid carcinoma of the lung is more commonly observed among elderly patients and adults.
  • Biphasic blastoma subtype is an exception and an average age of 35 years old patients being more commonly diagnosed

Race

  • There is no racial predilection to sarcomatoid carcinoma of the lung.

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. Franks TJ, Galvin JR (2010). "Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis". Arch. Pathol. Lab. Med. 134 (1): 49–54. doi:10.1043/2008-0547-RAR.1. PMID 20073605.
  2. Travis WD; Brambilla E; Müller-Hermelink K; Harris C; Kleihues C; Sobin P. https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |chapterurl= missing title (help) (PDF). World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart. IARC Press. pp. 53–58. ISBN ISBN 92 832 2418 3 Check |isbn= value: invalid character (help).
  3. Brambilla, E.; Travis, W.D.; Colby, T.V.; Corrin, B.; Shimosato, Y. (2001). "The new World Health Organization classification of lung tumours". European Respiratory Journal. 18 (6): 1059–1068. doi:10.1183/09031936.01.00275301. ISSN 0903-1936.
  4. Ouziane, Imane; Boutayeb, Saber; Mrabti, Hind; Lalya, Issam; Rimani, Mouna; Errihani, Hassan (2014). "Sarcomatoid carcinoma of the lung: A model of resistance of chemotherapy". North American Journal of Medical Sciences. 6 (7): 342. doi:10.4103/1947-2714.136920. ISSN 1947-2714.

Template:WH Template:WS